Percutaneous coronary intervention for chronic total occlusion (CTO PCI) is frequently offered to patients with stable angina, primarily for symptom and quality of life improvement. However, the efficacy of this intervention has lacked blinded, randomized evidence. The ORBITA-CTO trial, presented at ACC.26, directly addresses this gap, demonstrating that CTO PCI did not improve angina symptoms or quality of life compared to a placebo procedure.1
- The Pivot CTO PCI, previously offered for symptom relief, now lacks blinded randomized evidence for this indication.
- The Data There was no significant difference in the change in angina frequency score between CTO PCI and placebo (mean difference: -0.1, 95% CI: -1.2 to 1.0, p=0.85).
- The Action Clinicians should reconsider the routine recommendation of CTO PCI for symptom improvement in stable angina, given the absence of demonstrated benefit over placebo.
Chronic total occlusion (CTO) of a coronary artery is defined as complete obstruction with TIMI 0 flow for an estimated duration of at least three months. Percutaneous coronary intervention (PCI) for CTOs is a complex procedure, often undertaken with the primary goal of alleviating angina symptoms and improving patient quality of life in those with stable angina. Despite its widespread use, the evidence base for CTO PCI, particularly regarding its symptomatic benefits, has been limited by the absence of blinded, randomized controlled trials. This gap has meant that clinical decisions were often made without robust data comparing the intervention to a sham procedure, leaving uncertainty about the true efficacy of CTO PCI beyond the effects of medical therapy.1
The ORBITA-CTO Trial
The ORBITA-CTO trial was a randomized, placebo-controlled study designed to evaluate the efficacy of CTO PCI in improving angina symptoms and quality of life in patients with stable angina. The trial enrolled 200 patients with stable angina and at least one CTO, randomized in a 1:1 ratio to either CTO PCI or a placebo procedure. Patients were blinded to their treatment assignment. The primary endpoint was the change in angina frequency score from baseline to 6 weeks, measured using the Seattle Angina Questionnaire (SAQ). Secondary endpoints included changes in SAQ physical limitation score, quality of life scores, and exercise capacity.1
Patients in both arms received optimal medical therapy throughout the study. The placebo procedure involved a coronary angiogram without intervention, mimicking the diagnostic phase of the PCI procedure to maintain blinding. Technical success of CTO PCI was achieved in 85% of patients randomized to the active treatment arm.1
At 6 weeks, the trial found no significant difference in the primary endpoint. The mean change in angina frequency score from baseline was -0.1 (95% CI: -1.2 to 1.0, p=0.85) for CTO PCI compared to the placebo group. This indicates that CTO PCI did not provide a statistically significant improvement in angina frequency over the placebo procedure. Similarly, there were no significant differences observed in secondary endpoints, including changes in SAQ physical limitation score, other quality of life metrics, or exercise capacity between the two groups. The safety profile was comparable between the two arms, with no significant differences in major adverse cardiac events.1
The ORBITA-CTO trial provides critical blinded, randomized evidence regarding the symptomatic efficacy of CTO PCI in stable angina. The absence of a significant difference in angina relief or quality of life improvement between the active intervention and placebo procedure challenges the current practice of offering CTO PCI primarily for symptom management. The study's design, including blinding and a placebo control, strengthens the validity of its findings, addressing a long-standing evidence gap in interventional cardiology.1
The ORBITA-CTO trial delivers a clear message: the symptomatic benefit of CTO PCI in stable angina, when compared to a placebo procedure, is negligible. This finding should prompt a re-evaluation of current guidelines and clinical practice, particularly for patients whose primary indication for CTO PCI is angina relief. For too long, the absence of blinded evidence allowed for an assumption of benefit that this trial now directly refutes. Clinicians must now consider whether the risks and costs associated with a complex procedure like CTO PCI are justified when the primary outcome, symptom improvement, is not demonstrably better than a sham intervention.
The implications extend beyond individual patient discussions. Interventional cardiology societies and guideline bodies, such as the American College of Cardiology and the European Society of Cardiology, will need to integrate these data into their recommendations. The industry, particularly manufacturers of PCI devices and guidewires, may face scrutiny regarding the marketing and utilization of their products for this indication. The trial underscores the importance of rigorous, placebo-controlled studies, even for established procedures, to ensure that interventions truly deliver the intended patient benefit.
Patients with stable angina and CTOs, who are often seeking relief from debilitating symptoms, deserve interventions proven to be effective. This trial suggests that for many, the perceived benefit of CTO PCI may have been a placebo effect. Moving forward, the focus for these patients should remain on optimizing medical therapy and exploring other evidence-based approaches for symptom management, reserving CTO PCI for specific circumstances where a clear, non-symptomatic benefit can be demonstrated, or within the context of further research.
ART-2026-046
Cite This Article
Team TLSFE. Orbita-cto: cto pci offers no angina relief over placebo. The Life Science Feed. Updated May 19, 2026. Accessed May 20, 2026. https://thelifesciencefeed.com/cardiology/coronary-artery-disease/research/orbita-cto-pci-no-angina-relief-over-placebo.
Licence & Rights
© 2026 The Life Science Feed. All rights reserved. Unless otherwise indicated, all content is the property of The Life Science Feed and may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission.
Editorial & AI Standards
All content is researched from peer-reviewed, open-access sources — published trial data, clinical guidelines, and regulatory filings. AI tools are used solely to structure and summarise that evidence; no AI-generated conclusions appear without editor verification against the primary source.
Every article is reviewed by a named editor before publication. Source citations are listed in the References section. This content does not represent the views of any pharmaceutical company, medical device manufacturer, or healthcare provider.
References
1. Khan S, Sajjad U, Fawaz S. Randomized, Placebo-Controlled Trial of Chronic Total Occlusion Percutaneous Coronary Intervention in Stable Angina: The ORBITA-CTO Trial. J Am Coll Cardiol 2026;87(20):2000-2009.
